1 |
NCT03335670 |
Recruiting |
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors |
|
|
Interventional
|
Early Phase 1 |
- Yusuf Menda
- National Cancer Institute (NCI)
- National Institutes of Health (NIH)
- (and 2 more...)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Determine biodistribution (pharmacokinetic parameters) of [68Ga]Pentixafor in patients with neuroendocrine tumors (NETs)
- Determine the repeatability of [68Ga]Pentixafor uptake in known neuroendocrine tumor lesions
- Compare standardized uptake values of [68Ga]Pentixafor and [68Ga]DOTATATE in known neuroendocrine tumor lesions
- Correlate the uptake of [68Ga]Pentixafor and [68Ga]DOTATATE (NetSpot) in known neuroendocrine tumor lesions with expression of receptors (CXCR4 and SSTR2) in biopsy tissue samples.
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT03335670 |
201708705 P50CA174521 |
|
November 3, 2017 |
October 1, 2019 |
December 31, 2020 |
November 8, 2017 |
January 9, 2018 |
|
- Holden Comprehensive Cancer Center
Iowa City, Iowa, United States
|
|
2 |
NCT02420314 |
Recruiting |
Pharmacological Ascorbate for Lung Cancer |
- Carcinoma, Non-Small-Cell Lung
|
- Drug: Paclitaxel
- Drug: Carboplatin
- Drug: Ascorbic Acid
|
Interventional
|
Phase 2 |
- Joseph J. Cullen, MD, FACS
- National Cancer Institute (NCI)
- National Institutes of Health (NIH)
- (and 3 more...)
|
Other / NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tumor response
- Progression free survival (PFS)
- Overall survival (OS)
- Adverse Event Frequency
|
57 |
All |
18 Years and older (Adult, Older Adult) |
NCT02420314 |
201412760 3P30CA086862 |
|
April 2015 |
December 2020 |
December 2025 |
April 17, 2015 |
January 25, 2019 |
|
- Holden Comprehensive Cancer Center
Iowa City, Iowa, United States
|
|
3 |
NCT03044977 |
Recruiting |
Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors |
- Neuroendocrine Tumor, Malignant
- Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting
|
- Drug: 90Y-DOTA-3-Tyr-Octreotide
- Drug: 131I-MIBG
|
Interventional
|
Early Phase 1 |
- David Bushnell
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- (and 2 more...)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- glomular filtration rate (eGFR)
- urine protein
- platelet count decreased
- (and 3 more...)
|
20 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03044977 |
201608857 P50CA174521-02 |
|
May 7, 2017 |
December 31, 2020 |
December 31, 2022 |
February 7, 2017 |
April 17, 2018 |
|
- Holden Comprehensive Cancer Center
Iowa City, Iowa, United States
|
|
4 |
NCT02905578 |
Recruiting |
A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1) |
- Pancreatic Neoplasms
- Cancer of Pancreas
- Cancer of the Pancreas
- (and 4 more...)
|
- Drug: Gemcitabine
- Drug: nab-paclitaxel
- Drug: Pharmacological ascorbate
|
Interventional
|
Phase 2 |
- Joseph J. Cullen
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- (and 3 more...)
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Overall survival
- Tumor Response
- Progression free survival
- Adverse event frequency and categorization
|
65 |
All |
18 Years and older (Adult, Older Adult) |
NCT02905578 |
201801759 3P30CA086862 5U01CA140206 |
|
November 5, 2018 |
December 31, 2023 |
December 31, 2025 |
September 19, 2016 |
November 9, 2018 |
|
- Holden Comprehensive Cancer Center
Iowa City, Iowa, United States
|
|
5 |
NCT03724409 |
Recruiting |
Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases |
|
|
Interventional
|
Early Phase 1 |
- Sandeep Laroia
- National Institutes of Health (NIH)
- Holden Comprehensive Cancer Center
- (and 2 more...)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in liver enzymes
- Change in platelet counts
- Change in absolute neutrophil count
- 90Y-DOTATOC distribution
|
10 |
All |
18 Years and older (Adult, Older Adult) |
NCT03724409 |
201805910 P50CA174521 |
|
October 11, 2018 |
December 2025 |
December 2025 |
October 30, 2018 |
October 30, 2018 |
|
- The Holden Comprehensive Cancer Center
Iowa City, Iowa, United States
|
|
6 |
NCT02344355 |
Recruiting |
A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme |
|
- Drug: Temozolomide
- Radiation: radiation therapy
- Drug: Ascorbic Acid
|
Interventional
|
Phase 2 |
- Bryan Allen
- Holden Comprehensive Cancer Center
- National Cancer Institute (NCI)
- University of Iowa
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival (OS)
- Progression Free Survival (PFS)
- Adverse Event Frequency
|
90 |
All |
18 Years and older (Adult, Older Adult) |
NCT02344355 |
201504786 |
|
March 13, 2017 |
April 2020 |
December 2023 |
January 22, 2015 |
May 28, 2018 |
|
- Holden Comprehensive Cancer Center
Iowa City, Iowa, United States
|
|
7 |
NCT03541486 |
Not yet recruiting |
A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients |
|
- Drug: Ascorbate
- Drug: Gemcitabine
- Radiation: radiation therapy
|
Interventional
|
Phase 2 |
- Joseph J. Cullen
- Holden Comprehensive Cancer Center
- University of Iowa
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Objective response rate (ORR)
- Progression free survival (PFS)
- Toxicity over time (ToxT)
|
35 |
All |
18 Years and older (Adult, Older Adult) |
NCT03541486 |
XACT-PANC-2 |
XACT-PANC-2 |
April 1, 2019 |
December 31, 2028 |
December 31, 2030 |
May 30, 2018 |
May 30, 2018 |
|
- The University of Iowa
Iowa City, Iowa, United States
|
|
8 |
NCT03658343 |
Recruiting |
T2* MRI Analysis for Sarcoma |
- Radiotherapy
- Magnetic Resonance Imaging
- Sarcoma
|
- Diagnostic Test: T2* Imaging
|
Interventional
|
Not Applicable |
- Bryan Allen
- Holden Comprehensive Cancer Center
- National Cancer Institute (NCI)
- University of Iowa
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Change in ferric iron levels detected by T2* MRI
- Change in ferrous iron levels detected by T2* MRI
|
15 |
All |
18 Years and older (Adult, Older Adult) |
NCT03658343 |
T2*Sarc 5P30CA086862 |
|
September 18, 2018 |
December 31, 2020 |
December 31, 2021 |
September 5, 2018 |
December 10, 2018 |
|
- Holden Comprehensive Cancer Center
Iowa City, Iowa, United States
|
|
9 |
NCT02905591 |
Recruiting |
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC |
- Carcinoma, Non-Small-Cell Lung
- Non-Small Cell Lung Cancer
- Nonsmall Cell Lung Cancer
- (and 2 more...)
|
- Drug: Radiation Therapy
- Drug: Paclitaxel
- Drug: Carboplatin
- Drug: Ascorbic Acid
|
Interventional
|
Phase 2 |
- Joseph J. Cullen, MD, FACS
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- (and 2 more...)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression rate at completion of radiation and chemotherapy
- Tumor response
- Progression free survival (PFS)
- (and 2 more...)
|
46 |
All |
18 Years and older (Adult, Older Adult) |
NCT02905591 |
201712770 3P30CA086862 5U01CA140206 1P01CA217797-01A1 |
XACT-LUNG |
November 16, 2018 |
July 2024 |
July 2026 |
September 19, 2016 |
December 10, 2018 |
|
- Holden Comprehensive Cancer Cener
Iowa City, Iowa, United States
|
|
10 |
NCT03688347 |
Recruiting |
Microbiome in Lung Cancer and Other Malignancies |
- Lung Cancer
- Cancer
- Malignancy
|
- Procedure: Nasal Swab
- Procedure: Oral Swab
- Other: Stool Collection
- (and 3 more...)
|
Observational
|
|
- Jun Zhang, MD, PhD
- University of Iowa Holden Comprehensive Cancer Center
- Iowa Institute for Human Genetics
- (and 2 more...)
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Identify and compare bacteria within given samples through standard protocol and 16S rRNA amplicon
- Correlate data from samples with patient clinical information
- Number of treatment related adverse events (AE) as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
|
40 |
All |
18 Years to 100 Years (Adult, Older Adult) |
NCT03688347 |
201712819 |
|
August 30, 2018 |
August 2019 |
August 2019 |
September 28, 2018 |
January 14, 2019 |
|
- University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
|
|
11 |
NCT02959164 |
Recruiting |
Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma |
- Pancreatic Ductal Adenocarcinoma
- Sarcoma
|
- Drug: Decitabine
- Drug: Gemcitabine
|
Interventional
|
Phase 1 |
- Varun Monga
- Holden Comprehensive Cancer Center
- University of Iowa
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose Limiting Toxicity - To examine the toxicity related to the therapy by measuring the number of treatment related adverse events in patients
- Tumor Response Rate - Change at evaluations
- Disease control rate (DCR)
- (and 2 more...)
|
42 |
All |
18 Years and older (Adult, Older Adult) |
NCT02959164 |
201610750 |
|
December 2016 |
July 2019 |
July 2020 |
November 8, 2016 |
July 2, 2018 |
|
- University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
|
|
12 |
NCT03506139 |
Not yet recruiting |
Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma |
- Glioblastoma
- Glioblastoma Multiforme
|
- Radiation: External beam radiation therapy
|
Interventional
|
Phase 2 |
- John M. Buatti
- Holden Comprehensive Cancer Center
- University of Iowa
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Progression free survival (PFS)
- Identifying tissue at risk of recurrence
- (and 2 more...)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03506139 |
201801819 |
|
January 15, 2019 |
December 31, 2024 |
December 31, 2026 |
April 23, 2018 |
December 10, 2018 |
|
|
|
13 |
NCT03684785 |
Recruiting |
Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors |
- Advanced or Metastatic Solid Tumors
- Advanced or Metastatic Melanoma
- Advanced or Metastatic Head and Neck Squamous Cell Carcinoma
- (and 2 more...)
|
- Drug: AST-008
- Biological: Pembrolizumab
|
Interventional
|
Phase 1 Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Adverse events of AST-008 alone and in combination with pembrolizumab
- Recommended Phase 2 dose
- Disease assessment with RECIST 1.1
|
81 |
All |
18 Years and older (Adult, Older Adult) |
NCT03684785 |
AST-008-102 |
|
December 13, 2018 |
December 31, 2020 |
April 1, 2021 |
September 26, 2018 |
February 19, 2019 |
|
- John Wayne Cancer Institute / Providence St. John's Health Center
Santa Monica, California, United States - Sylvester Comprehensive Cancer Center
Miami, Florida, United States - Holden Comprehensive Cancer Center
Iowa City, Iowa, United States - Dana Farber Cancer Institute
Boston, Massachusetts, United States
|
|
14 |
NCT02876640 |
Recruiting |
Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer |
- Early-Stage Breast Carcinoma
- Invasive Breast Carcinoma
|
- Other: Laboratory Biomarker Analysis
- Drug: Retinoid 9cUAB30
- Procedure: Therapeutic Conventional Surgery
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Absolute change in Ki-67 expression in breast epithelial cells of patients treated with 9cUAB30 assessed by immunohistochemistry
- Change in apoptosis in breast epithelial cells of patients treated with 9cUAB30 assessed by TUNEL assay and immunohistochemistry
- Change in gene expression of breast cancer samples using a custom gene panel from Nanostring Technologies
- (and 2 more...)
|
40 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02876640 |
NCI-2016-01293 N01-CN-2012-00033 UW16063 UWI2015-05-01 N01CN00033 P30CA014520 |
|
March 16, 2018 |
April 1, 2020 |
April 1, 2020 |
August 24, 2016 |
February 15, 2019 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, United States - University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota, United States - (and 2 more...)
|
|
15 |
NCT01787409 |
Recruiting |
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency |
- Aggressive Non-Hodgkin Lymphoma
- Anaplastic Large Cell Lymphoma
- Angioimmunoblastic T-Cell Lymphoma
- (and 12 more...)
|
- Dietary Supplement: Cholecalciferol
- Other: Laboratory Biomarker Analysis
|
Interventional
|
Not Applicable |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event free survival (EFS) (Study I)
- Treatment free status (Study II)
- Bio-R response rate (Study II)
- (and 5 more...)
|
713 |
All |
18 Years and older (Adult, Older Adult) |
NCT01787409 |
LS1293 NCI-2013-00037 P30CA015083 |
|
March 6, 2013 |
November 2019 |
November 2019 |
February 8, 2013 |
January 4, 2019 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Emory University/Winship Cancer Institute
Atlanta, Georgia, United States - University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, United States - (and 2 more...)
|
|
16 |
NCT02194738 |
Recruiting |
Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) |
- Large Cell Lung Carcinoma
- Lung Adenocarcinoma
- Stage IB Non-Small Cell Lung Carcinoma AJCC v7
- (and 9 more...)
|
- Other: Clinical Observation
- Drug: Crizotinib
- Other: Cytology Specimen Collection Procedure
- (and 3 more...)
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Central clinical genotyping to facilitate accrual to the adjuvant Intergroup studies, E4512 and A081105, as measured by rate of accrual
- Feasibility of research grade formalin-fixed, paraffin-embedded tissue collection for Center for Cancer Genomics (CCG) analysis, as measured by adequate specimens collected per month
- Disease free survival (DFS) rate for lung cancers which are wild-type for EGFR and ALK
- Agreement of local genotyping methods (direct sequencing of EGFR, ALK fluorescence in situ hybridization [FISH]) with central Clinical Laboratory Improvement Amendments genotyping
|
8300 |
All |
18 Years and older (Adult, Older Adult) |
NCT02194738 |
NCI-2014-01509 A151216 U10CA180821 U10CA180830 U10CA031946 |
|
August 18, 2014 |
September 28, 2021 |
|
July 18, 2014 |
February 22, 2019 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 1406 more...)
|
|
17 |
NCT01901094 |
Recruiting |
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy |
- Stage II Breast Cancer
- Stage IIIA Breast Cancer
|
- Procedure: Axillary Lymph Node Dissection (ALND)
- Radiation: Nodal Radiation Therapy
- Radiation: Axillary Radiation Therapy
|
Interventional
|
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Canadian Cancer Trials Group
- Alliance for Clinical Trials in Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Invasive breast cancer recurrence-free interval (IBC-RFI)
- Overall survival
- Ipsilateral/local/regional invasive breast cancer recurrence (ILR-REC)
|
2918 |
All |
18 Years and older (Adult, Older Adult) |
NCT01901094 |
A011202 U10CA031946 NCI-2013-00875 |
|
February 2014 |
January 2024 |
|
July 17, 2013 |
February 20, 2019 |
|
- Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - Southern Cancer Center PC-Providence
Mobile, Alabama, United States - (and 1152 more...)
|
|
18 |
NCT02713386 |
Recruiting |
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Serous Neoplasm
- (and 19 more...)
|
- Drug: Carboplatin
- Other: Laboratory Biomarker Analysis
- Drug: Paclitaxel
- (and 2 more...)
|
Interventional
|
Phase 1 Phase 2 |
- NRG Oncology
- National Cancer Institute (NCI)
- NRG Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of hematologic (heme) dose-limiting toxicity assessed according to Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 (Phase I)
- Progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Phase II)
- Complete pathological response, defined as no evidence of disease on radiographic imaging at the time of radiographic tumor measurement (Phase II)
- (and 5 more...)
|
162 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02713386 |
NRG-GY007 NCI-2016-00203 U10CA180868 |
|
May 18, 2016 |
September 30, 2020 |
|
March 18, 2016 |
February 16, 2018 |
|
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States - University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, United States - Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, United States - (and 8 more...)
|
|
19 |
NCT01674140 |
Recruiting |
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer |
|
- Drug: anastrozole
- Drug: everolimus
- Drug: exemestane
- (and 5 more...)
|
Interventional
|
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Southwest Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- IDFS using a stratified log-rank test, assessed up to 10 years
- OS estimates will be based on Kaplan-Meier procedures, assessed up to 10 years
- DRFS, assessed up to 10 years
- Toxicity based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, assessed up to 10 years
|
1900 |
All |
18 Years and older (Adult, Older Adult) |
NCT01674140 |
S1207 U10CA032102 NCI-2012-01995 |
e3 |
April 2013 |
December 2022 |
January 2030 |
August 28, 2012 |
August 31, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 1454 more...)
|
|
20 |
NCT01479283 |
Recruiting |
Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) |
|
- Drug: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen
- Drug: 5-Days Prophylactic Cefazolin* Antibiotic Regimen
|
Interventional
|
Phase 3 |
- McMaster University
- Orthopedic Research and Education Foundation
- The Physicians' Services Incorporated Foundation
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Surgical Site Infections
- Functional Outcome and Quality of Life
- Antibiotic-Related Complications
- (and 3 more...)
|
600 |
All |
12 Years and older (Child, Adult, Older Adult) |
NCT01479283 |
GHRT01 |
PARITY |
January 2013 |
December 2020 |
December 2020 |
November 24, 2011 |
May 25, 2017 |
|
- Stanford University Hospital and Clinics
Redwood City, California, United States - University of California San Francisco Medical Center
San Francisco, California, United States - University of Connecticut Health Center
Farmington, Connecticut, United States - (and 39 more...)
|
|
21 |
NCT02921256 |
Recruiting |
Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer |
- Rectal Adenocarcinoma
- Stage II Rectal Cancer AJCC v7
- Stage III Rectal Cancer AJCC v7
|
- Drug: Capecitabine
- Drug: Fluorouracil
- Radiation: Intensity-Modulated Radiation Therapy
- (and 4 more...)
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in neoadjuvant rectal cancer (NAR) score
- Overall survival
- Disease free survival
- (and 2 more...)
|
348 |
All |
18 Years and older (Adult, Older Adult) |
NCT02921256 |
NCI-2016-00222 NRG-GI002 s17-00197 U10CA180868 |
|
October 12, 2016 |
April 30, 2019 |
|
October 3, 2016 |
February 22, 2019 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - Southern Cancer Center PC-Providence
Mobile, Alabama, United States - (and 619 more...)
|
|
22 |
NCT00898365 |
Recruiting |
Study of Kidney Tumors in Younger Patients |
- Clear Cell Sarcoma of the Kidney
- Congenital Mesoblastic Nephroma
- Diffuse Hyperplastic Perilobar Nephroblastomatosis
- (and 10 more...)
|
- Other: Cytology Specimen Collection Procedure
- Other: Laboratory Biomarker Analysis
|
Observational
|
|
- Children's Oncology Group
- National Cancer Institute (NCI)
- Children's Oncology Group
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Disease-free survival
- Overall survival
- Loss of heterozygosity (LOH testing discontinued as of April 2014)
|
5000 |
All |
up to 29 Years (Child, Adult) |
NCT00898365 |
AREN03B2 NCI-2009-00416 CDR0000459797 COG-AREN03B2 U10CA180886 U10CA098543 UG1CA189958 |
|
February 27, 2006 |
January 1, 2100 |
|
May 12, 2009 |
February 22, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - USA Health Strada Patient Care Center
Mobile, Alabama, United States - (and 243 more...)
|
|
23 |
NCT02750826 |
Recruiting |
Breast Cancer WEight Loss Study (BWEL Study) |
|
- Other: Health Education Program
- Other: Weight Loss Intervention
|
Interventional
|
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Division of Cancer Control
- (and 3 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Invasive disease-free survival
- Overall survival
- Distant disease-free survival
- (and 20 more...)
|
3136 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02750826 |
A011401 NCI-2015-01918 |
|
August 2016 |
May 2030 |
|
April 26, 2016 |
February 20, 2019 |
|
- Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - Southern Cancer Center PC-Providence
Mobile, Alabama, United States - (and 1350 more...)
|
|
24 |
NCT03377556 |
Recruiting |
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer |
- ATM Gene Mutation
- ATR Gene Mutation
- BARD1 Gene Mutation
- (and 18 more...)
|
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
- Drug: Talazoparib
|
Interventional
|
Phase 2 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Southwest Oncology Group
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate assessed by Response Evaluation Criteria in Solid Tumors 1.1 (Design #2)
- Duration of response (Design #2)
- Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Design #2)
- (and 2 more...)
|
64 |
All |
Child, Adult, Older Adult |
NCT03377556 |
S1400G NCI-2017-00135 U10CA180888 |
|
February 7, 2017 |
May 1, 2022 |
December 2024 |
December 19, 2017 |
August 31, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 1154 more...)
|
|
25 |
NCT03533582 |
Recruiting |
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery |
- Childhood Hepatocellular Carcinoma
- Childhood Malignant Liver Neoplasm
- Elevated Alpha-Fetoprotein
- (and 2 more...)
|
- Drug: Carboplatin
- Drug: Cisplatin
- Drug: Doxorubicin
- (and 9 more...)
|
Interventional
|
Phase 2 Phase 3 |
- Children's Oncology Group
- National Cancer Institute (NCI)
- Children's Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event-free survival (EFS)
- Response in hepatocellular carcinoma (HCC), defined as complete (CR) or partial (PR) response according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria
- Failure free survival
- (and 7 more...)
|
1220 |
All |
up to 30 Years (Child, Adult) |
NCT03533582 |
AHEP1531 NCI-2017-01910 U10CA180886 |
|
May 23, 2018 |
March 31, 2025 |
March 31, 2025 |
May 23, 2018 |
February 22, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - (and 122 more...)
|
|
26 |
NCT03220035 |
Recruiting |
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 22 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Vemurafenib
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate (ORR)
- Progress free survival (PFS)
- Incidence of adverse events evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03220035 |
NCI-2017-01244 APEC1621G U10CA180886 |
|
July 24, 2017 |
December 31, 2023 |
December 31, 2023 |
July 18, 2017 |
February 21, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 91 more...)
|
|
27 |
NCT02954874 |
Recruiting |
Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer |
- Estrogen Receptor Negative
- HER2/Neu Negative
- Invasive Breast Carcinoma
- (and 13 more...)
|
- Other: Laboratory Biomarker Analysis
- Other: Patient Observation
- Biological: Pembrolizumab
- (and 3 more...)
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Invasive disease-free survival (IDFS)
- Severity of fatigue measured by Patient Reported Outcomes Measurement Information System (PROMIS) fatigue scale
- Physical function reported by patients measured by Patient Reported Outcomes Measurement Information System (PROMIS) Global physical health scale
- (and 11 more...)
|
1000 |
All |
18 Years and older (Adult, Older Adult) |
NCT02954874 |
NCI-2016-01595 S1418/BR006 s16-02231 S1418 U10CA180888 |
|
November 15, 2016 |
May 31, 2026 |
|
November 4, 2016 |
February 22, 2019 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 700 more...)
|
|
28 |
NCT03233204 |
Recruiting |
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 29 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Olaparib
- Other: Pharmacological Study
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate (complete response/partial response) determined using Response Evaluation Criteria in Solid Tumors version 1.1
- Progression free survival (PFS)
- Incidence of toxicity evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0
- Pharmacokinetics (PK) of olaparib
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03233204 |
NCI-2017-00766 APEC1621H U10CA180886 |
|
July 24, 2017 |
September 30, 2024 |
September 30, 2024 |
July 28, 2017 |
February 19, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 90 more...)
|
|
29 |
NCT02785952 |
Recruiting |
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers |
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC v7
|
- Biological: Ipilimumab
- Other: Laboratory Biomarker Analysis
- Biological: Nivolumab
- (and 2 more...)
|
Interventional
|
Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Southwest Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Investigator-assessed progression-free survival as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (Design #1, Phase II)
- Less than 33% improvement in median investigator-assessed progression-free survival as defined as Response Evaluation Criteria in Solid Tumors version 1.1 (Design #1, Phase III)
- Overall survival
- (and 4 more...)
|
350 |
All |
18 Years and older (Adult, Older Adult) |
NCT02785952 |
S1400I NCI-2016-00050 U10CA180888 |
|
December 18, 2015 |
April 1, 2022 |
April 1, 2022 |
May 30, 2016 |
August 31, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 1204 more...)
|
|
30 |
NCT02997228 |
Recruiting |
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer |
- Colorectal Adenocarcinoma
- Mismatch Repair Deficiency
- Stage IV Colorectal Cancer AJCC v7
- (and 2 more...)
|
- Drug: Atezolizumab
- Biological: Bevacizumab
- Drug: Fluorouracil
- (and 4 more...)
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS)
- Overall survival (OS)
- Objective response rate (ORR) (complete response [CR] or partial response [PR]) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- (and 5 more...)
|
347 |
All |
18 Years and older (Adult, Older Adult) |
NCT02997228 |
NCI-2016-01961 NRG-GI004/S1610 NRG-GI004 U10CA180868 |
|
November 7, 2017 |
April 30, 2022 |
April 30, 2022 |
December 20, 2016 |
February 22, 2019 |
|
- Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, United States - John Muir Medical Center-Concord Campus
Concord, California, United States - Fremont - Rideout Cancer Center
Marysville, California, United States - (and 287 more...)
|
|
31 |
NCT00772200 |
Recruiting |
Neuropsychological and Behavioral Testing in Younger Patients With Cancer |
- Childhood Malignant Neoplasm
- Cognitive Side Effects of Cancer Therapy
|
- Procedure: Cognitive Assessment
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
|
Observational
|
|
- Children's Oncology Group
- National Cancer Institute (NCI)
- Children's Oncology Group
|
Other / NIH |
|
- Consistent, streamlined, and efficient administration of neuropsychological and behavioral tests
- Utilization of standardized battery of age-appropriate neuropsychological and behavioral tests in conjunction with COG Phase III clinical trials
- Percentage of patients who completed the assessment
|
755 |
All |
1 Month to 21 Years (Child, Adult) |
NCT00772200 |
ALTE07C1 NCI-2009-00383 COG-ALTE07C1 CDR0000594326 U10CA180886 U10CA098543 UG1CA189955 UG1CA189958 |
|
September 15, 2008 |
January 1, 2100 |
|
October 15, 2008 |
February 22, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - (and 178 more...)
|
|
32 |
NCT02867592 |
Recruiting |
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors |
- Adrenal Cortex Carcinoma
- Alveolar Soft Part Sarcoma
- Central Nervous System Neoplasm
- (and 33 more...)
|
- Drug: Cabozantinib S-malate
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response assessed by Response Evaluation Criteria in Solid Tumors version 1.1
- Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0
- Pharmacokinetics (PK) parameters of cabozantinib s-malate
|
146 |
All |
2 Years to 30 Years (Child, Adult) |
NCT02867592 |
NCI-2016-01258 ADVL1622 U10CA180886 |
|
May 8, 2017 |
June 30, 2021 |
June 30, 2021 |
August 16, 2016 |
February 22, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 131 more...)
|
|
33 |
NCT02177695 |
Recruiting |
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer |
|
- Drug: Gemcitabine
- Drug: Cisplatin
- Drug: Methotrexate
- (and 3 more...)
|
Interventional
|
Phase 2 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Southwest Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The relationship of dose-dense methotrexate, vinblastin, doxorubicin, and cisplatin (DDMVAC)- and gemcitabine+cisplatin (GC)- specific CO-eXpression ExtrapolatioN (COXEN) scores.
- Predictability of the CO-eXpression ExtrapolatioN (COXEN) score to direct which of the two regimens the patient should receive: gemcitabine+cisplatin (GC) versus dose-dense methotrexate, vinblastin, doxorubicin, and cisplatin (DDMVAC)
- Overall survival
- (and 2 more...)
|
184 |
All |
18 Years and older (Adult, Older Adult) |
NCT02177695 |
S1314 NCI-2014-00850 U10CA180888 |
COXEN |
July 2014 |
February 2020 |
October 2022 |
June 30, 2014 |
July 16, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Fairbanks Memorial Hospital
Fairbanks, Alaska, United States - University of Arizona Cancer Center at Saint Joseph's
Phoenix, Arizona, United States - (and 564 more...)
|
|
34 |
NCT01220583 |
Recruiting |
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery |
|
- Drug: cisplatin
- Radiation: 3-dimensional conformal radiation therapy
- Radiation: intensity-modulated radiation therapy
|
Interventional
|
Phase 2 |
- Radiation Therapy Oncology Group
- National Cancer Institute (NCI)
- NRG Oncology
- Radiation Therapy Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival (PFS), defined by the events of local-regional progression or recurrence, distant metastasis, or death from any cause, primarily at 2 years
- Overall survival (OS) rate at 2 years
- PFS rate at 5 years
- (and 6 more...)
|
120 |
All |
18 Years and older (Adult, Older Adult) |
NCT01220583 |
RTOG-1008 CDR0000686072 NCI-2013-00370 |
|
January 2011 |
October 2023 |
October 2028 |
October 14, 2010 |
August 31, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - The Kirklin Clinic at Acton Road
Birmingham, Alabama, United States - Arizona Breast Cancer Specialists-Gilbert
Gilbert, Arizona, United States - (and 230 more...)
|
|
35 |
NCT02143401 |
Recruiting |
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors |
- Cirrhosis
- Hepatitis B Infection
- Hepatitis C Infection
- (and 6 more...)
|
- Other: Laboratory Biomarker Analysis
- Biological: Navitoclax
- Other: Pharmacological Study
- Drug: Sorafenib Tosylate
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) of navitoclax
- Incidence of adverse events as graded per NCI CTCAE v. 4.0
- Tumor response using the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.1
- (and 5 more...)
|
44 |
All |
18 Years and older (Adult, Older Adult) |
NCT02143401 |
NCI-2014-01043 MC1315 9608 UM1CA186686 |
|
November 7, 2014 |
November 1, 2018 |
|
May 21, 2014 |
August 3, 2018 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - University of California Davis Comprehensive Cancer Center
Sacramento, California, United States - University of Colorado Hospital
Aurora, Colorado, United States - (and 7 more...)
|
|
36 |
NCT00082745 |
Recruiting |
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors |
- Cancer Survivor
- Cardiovascular Complication
- Childhood Malignant Neoplasm
|
- Other: Laboratory Biomarker Analysis
- Other: Questionnaire Administration
|
Observational
|
|
- Children's Oncology Group
- National Cancer Institute (NCI)
- Children's Oncology Group
|
Other / NIH |
|
- Rate of adverse events (cardiac dysfunction, AVN, ischemic stroke, and SMN using a matched case-control)
- Frequency of mutations or polymorphisms in specific candidate genes in cases and controls
- Crude disease-exposure
|
8100 |
All |
up to 21 Years (Child, Adult) |
NCT00082745 |
ALTE03N1 NCI-2011-03822 COG-ALTE03N1 CDR0000360708 U10CA180886 U10CA095861 UG1CA189955 UG1CA189958 |
|
March 22, 2004 |
January 1, 2100 |
|
May 19, 2004 |
February 22, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 151 more...)
|
|
37 |
NCT02154490 |
Recruiting |
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer |
- Recurrent Squamous Cell Lung Carcinoma
- Stage IV Squamous Cell Lung Carcinoma AJCC v7
|
- Drug: Docetaxel
- Biological: Durvalumab
- Drug: Erlotinib Hydrochloride
- (and 10 more...)
|
Interventional
|
Phase 2 Phase 3 |
- Southwest Oncology Group
- National Cancer Institute (NCI)
- Southwest Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Investigator-assessed progression-free survival as defined by Response Evaluation Criteria in Solid Tumors 1.1 (Design #1, Phase II)
- Investigator-assessed progression-free survival in patients with advanced stage refractory squamous cell carcinoma of the lung randomized to receive investigational therapy vs standard therapy (Design #2,Phase III,Option for Biomarker-driven sub-studies)
- Less than 33% improvement in median investigator-assessed progression-free survival as defined as Response Evaluation Criteria in Solid Tumors 1.1 (Design #1, Phase III)
- (and 13 more...)
|
10000 |
All |
18 Years and older (Adult, Older Adult) |
NCT02154490 |
S1400 NCI-2014-00627 S1400A S1400E S1400I S1400C S1400D S1400B U10CA180888 |
|
June 16, 2014 |
April 1, 2022 |
April 1, 2022 |
June 3, 2014 |
August 31, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 1001 more...)
|
|
38 |
NCT02201992 |
Recruiting |
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) |
- ALK Gene Rearrangement
- ALK Gene Translocation
- ALK Positive
- (and 5 more...)
|
- Other: Clinical Observation
- Drug: Crizotinib
- Other: Laboratory Biomarker Analysis
|
Interventional
|
Phase 3 |
- ECOG-ACRIN Cancer Research Group
- National Cancer Institute (NCI)
- Eastern Cooperative Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Disease free survival (DFS)
- Toxicity rates, determined using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
|
168 |
All |
18 Years and older (Adult, Older Adult) |
NCT02201992 |
E4512 NCI-2014-01507 s16-02072 U10CA180820 U10CA180830 U10CA021115 U24CA196172 |
|
August 18, 2014 |
May 1, 2022 |
|
July 28, 2014 |
February 6, 2019 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 1286 more...)
|
|
39 |
NCT02839707 |
Recruiting |
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Undifferentiated Carcinoma
- (and 10 more...)
|
- Drug: Atezolizumab
- Biological: Bevacizumab
- Other: Laboratory Biomarker Analysis
- (and 2 more...)
|
Interventional
|
Phase 2 Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of dose limiting toxicities (DLT) of experimental regimens graded using Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.0 (CTCAE version 5.0 will be used beginning April 1, 2018)
- Progression free survival (PFS) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version (v.) 1.1 criteria (Phase II)
- Overall survival (OS) (Phase III)
- (and 10 more...)
|
488 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02839707 |
NCI-2016-01081 NRG-GY009 U10CA180868 UG1CA189867 |
|
May 12, 2017 |
June 30, 2023 |
June 30, 2023 |
July 21, 2016 |
February 22, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 732 more...)
|
|
40 |
NCT03213704 |
Recruiting |
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 33 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Larotrectinib
- Other: Pharmacological Study
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate
- Progression free survival
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03213704 |
NCI-2017-01264 APEC1621A U10CA180886 |
|
July 24, 2017 |
September 30, 2024 |
September 30, 2024 |
July 11, 2017 |
February 15, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 93 more...)
|
|
41 |
NCT02595944 |
Recruiting |
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) |
- Stage IB Non-Small Cell Lung Carcinoma AJCC v7
- Stage II Non-Small Cell Lung Cancer AJCC v7
- Stage IIA Non-Small Cell Lung Carcinoma AJCC v7
- (and 2 more...)
|
- Other: Laboratory Biomarker Analysis
- Biological: Nivolumab
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Disease-free survival (DFS)
- Incidence of toxicity graded according to Common Terminology Criteria for Adverse Events version 5.0
|
714 |
All |
18 Years and older (Adult, Older Adult) |
NCT02595944 |
NCI-2015-01916 EA5142 s16-02074 U10CA180820 |
ANVIL |
May 6, 2016 |
July 1, 2024 |
|
November 4, 2015 |
February 22, 2019 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 841 more...)
|
|
42 |
NCT01042522 |
Recruiting |
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors |
- Ovarian Granulosa Cell Tumor
- Ovarian Gynandroblastoma
- Ovarian Sertoli-Leydig Cell Tumor
- (and 4 more...)
|
- Biological: Bleomycin Sulfate
- Drug: Carboplatin
- Drug: Cisplatin
- (and 3 more...)
|
Interventional
|
Phase 2 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival (PFS)
- Overall survival (OS)
- Tumor response rate
|
128 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01042522 |
GOG-0264 NCI-2011-02000 CDR0000662814 U10CA180868 U10CA027469 |
|
February 8, 2010 |
January 2, 2024 |
|
January 5, 2010 |
February 16, 2018 |
|
- Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Women's Cancer Care
Anchorage, Alaska, United States - Anchorage Oncology Centre
Anchorage, Alaska, United States - (and 193 more...)
|
|
43 |
NCT03067181 |
Recruiting |
Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors |
- Adult Germ Cell Tumor
- Childhood Extracranial Germ Cell Tumor
- Childhood Germ Cell Tumor
- (and 29 more...)
|
- Other: Best Practice
- Drug: Bleomycin
- Biological: Bleomycin Sulfate
- (and 8 more...)
|
Interventional
|
Phase 3 |
- Children's Oncology Group
- National Cancer Institute (NCI)
- Children's Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival
- Event-free survival
- Incidence of ototoxicity
- Content validity and understandability of Adolescents and Young Adults-Hearing Screen
|
1680 |
All |
up to 49 Years (Child, Adult) |
NCT03067181 |
AGCT1531 NCI-2017-00178 U10CA180886 |
|
May 8, 2017 |
June 30, 2027 |
June 30, 2027 |
March 1, 2017 |
February 19, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - USA Health Strada Patient Care Center
Mobile, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - (and 462 more...)
|
|
44 |
NCT03210714 |
Recruiting |
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 29 more...)
|
- Drug: Erdafitinib
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate
- Incidence of adverse events graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Progression free survival (PFS)
- Pharmacokinetic (PK) parameters
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03210714 |
NCI-2017-01159 APEC1621B U10CA180886 UM1CA081457 |
|
November 6, 2017 |
December 31, 2024 |
December 31, 2024 |
July 7, 2017 |
February 15, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 80 more...)
|
|
45 |
NCT03698994 |
Recruiting |
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- ARAF Gene Mutation
- BRAF Gene Mutation
- (and 43 more...)
|
- Other: Pharmacokinetic Study
- Drug: Ulixertinib
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate (ORR = complete response [CR] + partial response [PR]) in pediatric patients treated with BVD-523FB (ulixertinib)
- Progression free survival (PFS) in pediatric patients treated with ulixertinib
- Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events version 5.0
- Preliminary estimates of the pharmacokinetics of ulixertinib in children and adolescents with relapsed or refractory cancer
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03698994 |
NCI-2018-02150 APEC1621J U10CA180886 |
|
October 1, 2018 |
December 31, 2025 |
December 31, 2025 |
October 8, 2018 |
February 18, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 60 more...)
|
|
46 |
NCT03080883 |
Recruiting |
Apixaban in Preventing Secondary Cancer Related Blood Clots in Cancer Patients Who Have Completed Anticoagulation Therapy |
- Cerebral Vein Thrombosis
- Deep Vein Thrombosis
- Malignant Neoplasm
- (and 3 more...)
|
|
Interventional
|
Phase 3 |
- Academic and Community Cancer Research United
- National Cancer Institute (NCI)
- Academic and Community Cancer Research United
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Proportion of patients who experience at least one bleeding event
- Proportion of patients who experienced at least one bleeding event
- Venous thromboembolism recurrence
|
370 |
All |
18 Years and older (Adult, Older Adult) |
NCT03080883 |
ACCRU-SC-1601 NCI-2017-00325 P30CA015083 |
|
July 14, 2017 |
May 1, 2020 |
May 1, 2023 |
March 15, 2017 |
February 20, 2019 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Mayo Clinic in Florida
Jacksonville, Florida, United States - Illinois Cancer Center
Chicago, Illinois, United States - (and 18 more...)
|
|
47 |
NCT03030378 |
Recruiting |
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors |
- Metastatic Malignant Solid Neoplasm
- Unresectable Solid Neoplasm
|
- Other: Laboratory Biomarker Analysis
- Biological: Pembrolizumab
- Biological: Recombinant Interleukin-12
|
Interventional
|
Phase 1 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose
- Recommended phase 2 dose
- Progression free survival
- (and 5 more...)
|
36 |
All |
18 Years and older (Adult, Older Adult) |
NCT03030378 |
NCI-2017-00091 HCC 17-003 10061 UM1CA186690 |
|
August 11, 2017 |
August 31, 2020 |
August 31, 2020 |
January 25, 2017 |
February 15, 2019 |
|
- UC San Diego Moores Cancer Center
La Jolla, California, United States - University of California Davis Comprehensive Cancer Center
Sacramento, California, United States - UCSF Medical Center-Mount Zion
San Francisco, California, United States - (and 21 more...)
|
|
48 |
NCT01101451 |
Recruiting |
Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery |
- Cervical Adenocarcinoma
- Cervical Adenosquamous Carcinoma
- Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- (and 3 more...)
|
- Drug: Cisplatin
- Radiation: External Beam Radiation Therapy
- Radiation: Intensity-Modulated Radiation Therapy
- (and 2 more...)
|
Interventional
|
Phase 3 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- RFS
- Incidence of adverse events graded according to the active version of CTCAE
- Local control
- (and 5 more...)
|
534 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01101451 |
GOG-0263 NCI-2011-02037 CDR0000670125 U10CA180868 U10CA027469 |
|
April 12, 2010 |
December 31, 2020 |
|
April 12, 2010 |
August 24, 2017 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 630 more...)
|
|
49 |
NCT03155620 |
Recruiting |
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 42 more...)
|
- Procedure: Biopsy
- Procedure: Biospecimen Collection
- Drug: Ensartinib
- (and 12 more...)
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Objective response rate (complete response/partial response) assessed according to Response Evaluation Criteria in Solid Tumors version 1.1
- Incidence of toxicity assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0
- Incidence of research biopsy related target toxicity
- (and 2 more...)
|
1000 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03155620 |
NCI-2017-01251 APEC1621SC U10CA180886 |
|
July 24, 2017 |
September 30, 2027 |
September 30, 2027 |
May 16, 2017 |
February 22, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - (and 127 more...)
|
|
50 |
NCT02402244 |
Recruiting |
Project: Every Child for Younger Patients With Cancer |
- Central Nervous System Neoplasm
- Childhood Immature Teratoma
- Childhood Langerhans Cell Histiocytosis
- (and 7 more...)
|
- Other: Cytology Specimen Collection Procedure
- Other: Medical Chart Review
|
Observational
|
|
- Children's Oncology Group
- National Cancer Institute (NCI)
- Children's Oncology Group
|
Other / NIH |
|
- Preservation of clinically annotated, adequately preserved biological specimens for future research efforts
|
33000 |
All |
up to 25 Years (Child, Adult) |
NCT02402244 |
APEC14B1 NCI-2014-02057 U10CA098543 |
|
October 26, 2015 |
December 14, 2020 |
|
March 30, 2015 |
February 22, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - USA Health Strada Patient Care Center
Mobile, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - (and 225 more...)
|
|
51 |
NCT03213678 |
Recruiting |
PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Non-Hodgkin Lymphoma
- (and 32 more...)
|
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
- Drug: PI3K/mTOR Inhibitor LY3023414
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate
- Incidence of adverse events graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0
- Progression free survival (PFS)
- Pharmacokinetic (PK) parameters
|
144 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03213678 |
NCI-2017-01249 APEC1621D U10CA180886 |
|
July 31, 2017 |
September 30, 2024 |
September 30, 2024 |
July 11, 2017 |
February 18, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 91 more...)
|
|
52 |
NCT03213691 |
Recruiting |
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma
- (and 16 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Selumetinib
- Drug: Selumetinib Sulfate
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate
- Incidence of adverse events
- Progression free survival (PFS)
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03213691 |
NCI-2017-01250 APEC1621E U10CA180886 |
|
July 24, 2017 |
September 30, 2024 |
September 30, 2024 |
July 11, 2017 |
February 22, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 93 more...)
|
|
53 |
NCT03526250 |
Recruiting |
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- RB1 Positive
- Recurrent Childhood Ependymoma
- (and 30 more...)
|
- Other: Laboratory Biomarker Analysis
- Drug: Palbociclib
- Other: Pharmacological Study
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate defined as a patient who achieves a best response of partial response or complete response on the study
- Progression free survival (PFS)
- Incidence of adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0
- Pharmacokinetic (PK) parameters
|
49 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03526250 |
NCI-2018-00863 APEC1621I U10CA180886 |
|
June 22, 2018 |
March 30, 2023 |
March 30, 2023 |
May 16, 2018 |
February 15, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 61 more...)
|
|
54 |
NCT02193282 |
Recruiting |
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) |
- ALK Gene Rearrangement
- EGFR Exon 19 Deletion Mutation
- EGFR NP_005219.2:p.L858R
- (and 5 more...)
|
- Other: Clinical Observation
- Drug: Erlotinib Hydrochloride
- Other: Laboratory Biomarker Analysis
- Other: Placebo
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS)
- Disease free survival (DFS) rate
- Overall survival (OS) rate at 5 years
- (and 3 more...)
|
450 |
All |
18 Years and older (Adult, Older Adult) |
NCT02193282 |
NCI-2014-01508 s16-02079 CALGB A081105 A081105 U10CA180821 U10CA180830 U10CA031946 |
|
August 18, 2014 |
November 4, 2020 |
|
July 17, 2014 |
February 22, 2019 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Southern Cancer Center PC-Daphne
Daphne, Alabama, United States - Southern Cancer Center PC-Mobile
Mobile, Alabama, United States - (and 1357 more...)
|
|
55 |
NCT03213652 |
Recruiting |
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) |
- Advanced Malignant Solid Neoplasm
- ALK Fusion Protein Expression
- ALK Gene Mutation
- (and 15 more...)
|
- Drug: Ensartinib
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate
- Incidence of toxicity
- Progression free survival (PFS)
|
98 |
All |
12 Months to 21 Years (Child, Adult) |
NCT03213652 |
NCI-2017-01243 APEC1621F U10CA180886 |
|
July 24, 2017 |
September 30, 2024 |
September 30, 2024 |
July 11, 2017 |
February 22, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 90 more...)
|
|
56 |
NCT01872975 |
Recruiting |
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery |
- Stage IB Breast Cancer
- Stage II Breast Cancer
|
- Radiation: regional nodal XRT
- Radiation: chestwall XRT
- Radiation: WBI
|
Interventional
|
Not Applicable |
- NSABP Foundation Inc
- National Cancer Institute (NCI)
- Radiation Therapy Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- IBC-RFI
- OS
- LRRFI
- (and 6 more...)
|
1636 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01872975 |
NSABP-B-51 NCI-2012-03198 U10CA012027 |
|
August 2013 |
July 2023 |
August 2028 |
June 7, 2013 |
May 16, 2017 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - (and 518 more...)
|
|
57 |
NCT02502266 |
Recruiting |
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
- Deleterious BRCA1 Gene Mutation
- Deleterious BRCA2 Gene Mutation
- Fallopian Tube Clear Cell Adenocarcinoma
- (and 14 more...)
|
- Drug: Cediranib Maleate
- Other: Laboratory Biomarker Analysis
- Drug: Olaparib
- (and 4 more...)
|
Interventional
|
Phase 2 Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival (PFS) (Phase II and Phase III)
- Overall survival (OS) (Phase III)
- Objective response rate (partial or complete response) (Phase II and Phase III)
- Incidence of adverse events (Phase II and Phase III)
|
680 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02502266 |
NCI-2015-00651 s16-01681 NRG-GY005 U10CA180868 |
|
February 5, 2016 |
June 30, 2023 |
|
July 20, 2015 |
February 22, 2019 |
|
- Alaska Women's Cancer Care
Anchorage, Alaska, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - (and 316 more...)
|
|
58 |
NCT03602586 |
Recruiting |
Pembrolizumab and Epacadostat in Treating Patients With Recurrent, Persistent, or Progressive Ovarian Clear Cell Carcinoma |
- Malignant Ovarian Clear Cell Tumor
- Recurrent Ovarian Carcinoma
|
- Drug: Epacadostat
- Biological: Pembrolizumab
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete or partial objective tumor response
- Nature and degree of adverse events
- Progression-free survival (PFS)
- Overall survival (OS)
|
23 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03602586 |
NCI-2018-01561 NRG-GY016 U10CA180868 |
|
September 28, 2018 |
April 30, 2021 |
April 30, 2021 |
July 27, 2018 |
February 15, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - (and 244 more...)
|
|
59 |
NCT00492778 |
Recruiting |
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer |
- Endometrial Adenocarcinoma
- Endometrial Adenosquamous Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- (and 3 more...)
|
- Radiation: 3-Dimensional Conformal Radiation Therapy
- Drug: Cisplatin
- Radiation: Intensity-Modulated Radiation Therapy
- Radiation: Internal Radiation Therapy
|
Interventional
|
Phase 2 |
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
- Gynecologic Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Duration of progression-free survival
- Duration of overall survival
- Incidence of adverse effects graded by CTCAE version 3.0
- Prognostic significance of tumor size, tumor location (vaginal only vs. all others) and histology
|
164 |
Female |
Child, Adult, Older Adult |
NCT00492778 |
GOG-0238 NCI-2009-00603 CDR0000550975 U10CA180868 U10CA027469 |
|
February 25, 2008 |
July 1, 2022 |
|
June 27, 2007 |
February 16, 2018 |
|
- Sutter Auburn Faith Hospital
Auburn, California, United States - Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California, United States - Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, United States - (and 437 more...)
|
|
60 |
NCT00736749 |
Recruiting |
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies |
- Acute Lymphoblastic Leukemia
- Brain Neoplasm
- Hematopoietic Cell Transplantation Recipient
- (and 3 more...)
|
- Procedure: Assessment of Therapy Complications
- Other: Questionnaire Administration
|
Observational
|
|
- Children's Oncology Group
- National Cancer Institute (NCI)
- Children's Oncology Group
|
Other / NIH |
|
- Percentage of patients enrolled
- Percentage of patients in which long-term (20+ years) contact is maintained
- Percentage of eligible patients located who were lost to follow-up
- (and 3 more...)
|
4738 |
All |
Child, Adult, Older Adult |
NCT00736749 |
ALTE05N1 NCI-2009-00382 PALTE05N1_A06PAMDREVW01 CDR0000590123 U10CA180886 U10CA098543 UG1CA189955 UG1CA189958 |
|
May 19, 2008 |
January 31, 2100 |
|
August 18, 2008 |
February 22, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - USA Health Strada Patient Care Center
Mobile, Alabama, United States - (and 161 more...)
|
|
61 |
NCT02135042 |
Recruiting |
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA |
- Epstein-Barr Virus Infection
- Stage II Nasopharyngeal Carcinoma
- Stage III Nasopharyngeal Carcinoma
- (and 2 more...)
|
- Drug: Cisplatin
- Other: Clinical Observation
- Drug: Fluorouracil
- (and 5 more...)
|
Interventional
|
Phase 2 Phase 3 |
- NRG Oncology
- National Cancer Institute (NCI)
- NRG Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS) (Undetectable Plasma EBV DNA Cohort Phase III)
- Progression-free survival (PFS) (Detectable Plasma EBV DNA Cohort Phase II)
- Changes in pure tone audiometry (Phase II and III)
- (and 12 more...)
|
758 |
All |
18 Years and older (Adult, Older Adult) |
NCT02135042 |
NRG-HN001 NCI-2014-00635 RTOG-1305 U10CA180868 U10CA021661 |
|
April 2014 |
July 2021 |
July 2026 |
May 9, 2014 |
February 20, 2019 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - The Kirklin Clinic at Acton Road
Birmingham, Alabama, United States - The University of Arizona Medical Center-University Campus
Tucson, Arizona, United States - (and 154 more...)
|
|
62 |
NCT00904241 |
Recruiting |
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma |
- Ganglioneuroblastoma
- Localized Resectable Neuroblastoma
- Localized Unresectable Neuroblastoma
- (and 3 more...)
|
- Other: Cytology Specimen Collection Procedure
- Other: Laboratory Biomarker Analysis
|
Observational
|
|
- Children's Oncology Group
- National Cancer Institute (NCI)
- Children's Oncology Group
|
Other / NIH |
|
- Factors currently used for risk-group assignment (DNA content, MYCN copy number, and tumor histology)
- Prevalence of 1p, 11q, 14q, and 17q allelic status
- MYCN copy number by quantitative PCR
- (and 8 more...)
|
10000 |
All |
up to 30 Years (Child, Adult) |
NCT00904241 |
ANBL00B1 NCI-2009-00397 CDR0000078642 U10CA180886 U10CA098543 UG1CA189958 |
|
November 6, 2000 |
January 1, 2100 |
|
May 19, 2009 |
February 22, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - USA Health Strada Patient Care Center
Mobile, Alabama, United States - (and 256 more...)
|
|
63 |
NCT03418038 |
Recruiting |
Ascorbic Acid and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma |
- High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Hodgkin Lymphoma
- (and 3 more...)
|
- Dietary Supplement: Ascorbic Acid
- Drug: Carboplatin
- Drug: Cisplatin
- (and 10 more...)
|
Interventional
|
Phase 2 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- ORR (Arm C) defined as an objective status of CR or PR evaluated by RECIL criteria after 2 cycles of treatment
- Overall response rate (ORR) (Arms A and B) defined as an objective status of complete response (CR) or partial response (PR) evaluated by Response Evaluation Criteria in Lymphoma (RECIL) criteria after 2 courses of treatment in all arms
- Clinical benefit rate
- (and 6 more...)
|
151 |
All |
18 Years and older (Adult, Older Adult) |
NCT03418038 |
LS1781 NCI-2018-00057 P30CA015083 |
|
March 23, 2018 |
March 15, 2024 |
March 15, 2024 |
February 1, 2018 |
March 27, 2018 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Mayo Clinic in Florida
Jacksonville, Florida, United States - University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, United States - Mayo Clinic
Rochester, Minnesota, United States
|
|
64 |
NCT02926911 |
Recruiting |
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS |
- DCIS
- Ductal Carcinoma in Situ
|
- Other: Guideline Concordant Care
- Other: Active Surveillance
|
Interventional
|
Not Applicable |
- Alliance Foundation Trials, LLC.
- Patient-Centered Outcomes Research Institute
- Duke University
- (and 4 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of new diagnoses of ipsilateral invasive cancer in GCC and AS arms at 2 years of follow up
- Quality of Life (QOL)
- Psychological outcomes
- (and 11 more...)
|
1200 |
Female |
40 Years to 99 Years (Adult, Older Adult) |
NCT02926911 |
AFT-25 |
COMET |
February 22, 2017 |
June 2023 |
July 2023 |
October 6, 2016 |
February 11, 2019 |
|
- Providence Alaska Medical Center
Anchorage, Alaska, United States - Cedars-Sinai Medical Center
Los Angeles, California, United States - Sharp Memorial Hospital
San Diego, California, United States - (and 116 more...)
|
|
65 |
NCT03141684 |
Recruiting |
Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery |
- Metastatic Alveolar Soft Part Sarcoma
|
- Drug: Atezolizumab
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate evaluated using Response Evaluation Criteria in Solid Tumors version 1.1
- Duration of response using Response Evaluation Criteria in Solid Tumors version 1.1
- Progression free survival evaluated using Response Evaluation Criteria in Solid Tumors version 1.1
- (and 2 more...)
|
35 |
All |
6 Years and older (Child, Adult, Older Adult) |
NCT03141684 |
NCI-2016-01040 17-C-007 CC 17-C-0074 10005 ZIABC011078 |
|
March 3, 2017 |
December 1, 2018 |
December 1, 2018 |
May 5, 2017 |
December 10, 2018 |
|
- Mayo Clinic Hospital
Phoenix, Arizona, United States - Mayo Clinic in Arizona
Scottsdale, Arizona, United States - Los Angeles County-USC Medical Center
Los Angeles, California, United States - (and 34 more...)
|
|
66 |
NCT02306161 |
Recruiting |
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma |
- Metastatic Ewing Sarcoma
- Metastatic Malignant Neoplasm in the Bone
- Metastatic Malignant Neoplasm in the Bone Marrow
- (and 3 more...)
|
- Drug: Cyclophosphamide
- Drug: Doxorubicin Hydrochloride
- Drug: Etoposide
- (and 8 more...)
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to adverse analytic event (event-free survival [EFS]), defined to be disease-related event, diagnosis of a second malignant neoplasm, or death
- Overall Survival
- Overall toxicity of the addition of ganitumab to vincristine sulfate, doxorubicin hydrochloride and cyclophosphamide (VDC)/ifosfamide and etoposide (IE), using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- (and 6 more...)
|
330 |
All |
up to 50 Years (Child, Adult) |
NCT02306161 |
NCI-2014-02380 AEWS1221 s15-00442 U10CA180886 U10CA098543 |
|
December 8, 2014 |
December 31, 2020 |
December 31, 2020 |
December 3, 2014 |
February 15, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - USA Health Strada Patient Care Center
Mobile, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - (and 314 more...)
|
|
67 |
NCT02724579 |
Recruiting |
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma |
- Medulloblastoma
- Untreated Childhood Medulloblastoma
|
- Drug: Cisplatin
- Drug: Cyclophosphamide
- Other: Laboratory Biomarker Analysis
- (and 3 more...)
|
Interventional
|
Phase 2 |
- Children's Oncology Group
- National Cancer Institute (NCI)
- Children's Oncology Group
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PFS
- DNA methylation profiling as real-time classification of WNT-driven medulloblastoma
- Change in neurocognitive function (cognitive, social, emotional and behavioral) according to Children Oncology Group Standard Neuropsychological Battery
|
45 |
All |
3 Years to 21 Years (Child, Adult) |
NCT02724579 |
ACNS1422 NCI-2016-00150 U10CA180886 |
|
October 2, 2017 |
May 31, 2025 |
May 31, 2025 |
March 31, 2016 |
February 22, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - (and 167 more...)
|
|
68 |
NCT02166463 |
Recruiting |
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB or Stage IIIB-IVB Hodgkin Lymphoma |
- Ann Arbor Stage IIB Hodgkin Lymphoma
- Ann Arbor Stage IIIB Hodgkin Lymphoma
- Ann Arbor Stage IV Hodgkin Lymphoma
- (and 4 more...)
|
- Biological: Bleomycin Sulfate
- Drug: Brentuximab Vedotin
- Drug: Cyclophosphamide
- (and 8 more...)
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Event free survival (EFS), where events include disease progression or relapse, second malignancy, or death
- Proportion of patients with early response defined as no slow responding lesions (SRL) and no progressive disease (PD) at all sites determined by positron emission tomography (PET) per Deauville criteria through central review
- Proportion of patients needing protocol-directed radiation therapy (RT) defined as patients with slow responding lesions (SRL) or progressive disease (PD)
- Proportion of patients experiencing grade 3+ peripheral neuropathy assessed by modified Balis scale
|
600 |
All |
2 Years to 22 Years (Child, Adult) |
NCT02166463 |
NCI-2014-01223 s15-00950 AHOD1331 U10CA180886 |
|
March 16, 2015 |
December 31, 2020 |
|
June 18, 2014 |
February 15, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - USA Health Strada Patient Care Center
Mobile, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - (and 195 more...)
|
|
69 |
NCT03126916 |
Recruiting |
Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma |
- Childhood Ganglioneuroblastoma
- Childhood Neuroblastoma
- INRG Stage L2
- (and 4 more...)
|
- Biological: Aldesleukin
- Procedure: Autologous Hematopoietic Stem Cell Transplantation
- Drug: Busulfan
- (and 19 more...)
|
Interventional
|
Phase 3 |
- Children's Oncology Group
- National Cancer Institute (NCI)
- Children's Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event free survival (EFS) rate
- Non-inferiority of 131I-MIBG plus busulfan/melphalan (BuMel) and 131I-MIBG plus tandem transplant
- Incidence of adverse events, graded according to the National Cancer Institute Common Terminology Criteria version 5.0
|
774 |
All |
365 Days to 30 Years (Child, Adult) |
NCT03126916 |
ANBL1531 NCI-2016-01734 U10CA180886 |
|
May 9, 2018 |
June 30, 2026 |
June 30, 2026 |
April 25, 2017 |
February 22, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - Loma Linda University Medical Center
Loma Linda, California, United States - (and 94 more...)
|
|
70 |
NCT03007147 |
Recruiting |
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia |
- B Acute Lymphoblastic Leukemia
- BCR-ABL1 Fusion Protein Expression
- Minimal Residual Disease
- (and 4 more...)
|
- Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
- Drug: Cyclophosphamide
- Drug: Cytarabine
- (and 19 more...)
|
Interventional
|
Phase 3 |
- Children's Oncology Group
- National Cancer Institute (NCI)
- University of Milano Bicocca
- Children's Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease free survival (DFS)
- Imatinib mesylate administration after allogeneic hematopoietic stem cell transplantation (HSCT) in high risk Ph+ ALL patients
- Event free survival (EFS) of high risk pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission, and post-HSCT imatinib mesylate
- (and 5 more...)
|
700 |
All |
2 Years to 21 Years (Child, Adult) |
NCT03007147 |
AALL1631 NCI-2016-01588 U10CA180886 2017-000705-20 EsPhALL2017 |
|
July 28, 2017 |
June 30, 2028 |
June 30, 2028 |
January 2, 2017 |
February 15, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 138 more...)
|
|
71 |
NCT03180268 |
Recruiting |
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery |
- Grade II Meningioma
- Intracranial Meningioma
|
- Other: Clinical Observation
- Radiation: Radiation Therapy
|
Interventional
|
Phase 3 |
- NRG Oncology
- National Cancer Institute (NCI)
- NRG Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-Free Survival (PFS)
- Overall Survival (OS)
- 5 Year Overall Survival (OS)
- (and 9 more...)
|
148 |
All |
18 Years and older (Adult, Older Adult) |
NCT03180268 |
NRG-BN003 NCI-2016-01619 U10CA180868 |
|
June 14, 2017 |
June 15, 2027 |
August 31, 2027 |
June 8, 2017 |
January 29, 2019 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Saint Joseph's Hospital and Medical Center
Phoenix, Arizona, United States - Mayo Clinic Hospital
Phoenix, Arizona, United States - (and 113 more...)
|
|
72 |
NCT03581292 |
Recruiting |
Veliparib, Radiation Therapy, and Temozolomide in Treating Participants With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600E Mutations |
- Anaplastic Astrocytoma
- Glioblastoma
- Malignant Glioma
|
- Radiation: Radiation Therapy
- Drug: Temozolomide
- Drug: Veliparib
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event free survival (EFS)
- Objective response (OR)
- Overall survival (OS)
|
115 |
All |
3 Years to 25 Years (Child, Adult) |
NCT03581292 |
NCI-2018-01361 ACNS1721 U10CA180886 |
|
October 31, 2018 |
October 29, 2024 |
October 29, 2024 |
July 10, 2018 |
February 22, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 68 more...)
|
|
73 |
NCT03206450 |
Recruiting |
Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors |
- Cancer Survivor
- Osteosarcoma
|
- Procedure: Biospecimen Collection
- Other: Laboratory Biomarker Analysis
- Other: Questionnaire Administration
|
Observational
|
|
- Children's Oncology Group
- National Cancer Institute (NCI)
- Children's Oncology Group
|
Other / NIH |
|
- Infertility
- Follicle stimulating hormone levels
- Luteinizing hormone levels
- (and 5 more...)
|
331 |
Male |
18 Years to 50 Years (Adult) |
NCT03206450 |
ALTE16C1 NCI-2017-01152 COG-ALTE16C1 R01CA175216 |
|
October 10, 2017 |
September 5, 2021 |
September 5, 2021 |
July 2, 2017 |
February 22, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - Kaiser Permanente Downey Medical Center
Downey, California, United States - (and 65 more...)
|
|
74 |
NCT03190915 |
Recruiting |
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia |
- Activating RAS Mutation
- Blasts Under 20 Percent of Bone Marrow Nucleated Cells
- Blasts Under 20 Percent of Peripheral Blood White Cells
- (and 6 more...)
|
- Other: Laboratory Biomarker Analysis
- Other: Pharmacological Study
- Drug: Trametinib
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response
- Incidence of adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0
- Pharmacokinetic (PK) parameters of trametinib
|
24 |
All |
1 Month to 21 Years (Child, Adult) |
NCT03190915 |
NCI-2017-00921 ADVL1521 U10CA180886 |
|
October 6, 2017 |
December 30, 2020 |
December 30, 2020 |
June 19, 2017 |
February 19, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 40 more...)
|
|
75 |
NCT02176967 |
Recruiting |
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma |
- Ganglioneuroblastoma
- Localized Resectable Neuroblastoma
- Localized Unresectable Neuroblastoma
- (and 2 more...)
|
- Drug: Carboplatin
- Other: Clinical Observation
- Drug: Cyclophosphamide
- (and 4 more...)
|
Interventional
|
Phase 3 |
- Children's Oncology Group
- National Cancer Institute (NCI)
- Children's Oncology Group
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival (OS) (Strata 1-4)
- Event-free survival (EFS)
- Time to intervention or tumor progression
- (and 8 more...)
|
621 |
All |
up to 17 Months (Child) |
NCT02176967 |
ANBL1232 NCI-2014-00677 s15-00462 U10CA180886 U10CA098543 |
|
July 28, 2014 |
June 30, 2026 |
|
June 27, 2014 |
February 22, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - USA Health Strada Patient Care Center
Mobile, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - (and 209 more...)
|
|
76 |
NCT02628405 |
Recruiting |
R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma |
- CD20 Positive
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- (and 6 more...)
|
- Drug: Carboplatin
- Drug: Etoposide
- Drug: Ifosfamide
- (and 3 more...)
|
Interventional
|
Phase 1 Phase 2 |
- Academic and Community Cancer Research United
- National Cancer Institute (NCI)
- Academic and Community Cancer Research United
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients of the addition of lenalidomide to rituximab-ifosfamide-carboplatin-etoposide (Phase I)
- Toxicity profile defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment as measured by Common Terminology Criteria for Adverse Events version 4.0 (Phase I)
- Overall response rate defined as a complete metabolic response or partial metabolic response (Phase II)
- (and 4 more...)
|
63 |
All |
18 Years and older (Adult, Older Adult) |
NCT02628405 |
RU051417I NCI-2015-01990 P30CA015083 |
|
May 20, 2016 |
May 20, 2019 |
January 20, 2023 |
December 11, 2015 |
January 23, 2019 |
|
- Mayo Clinic in Florida
Jacksonville, Florida, United States - Illinois CancerCare-Peoria
Peoria, Illinois, United States - Carle Cancer Center NCI Community Oncology Research Program
Urbana, Illinois, United States - (and 12 more...)
|
|
77 |
NCT02521493 |
Recruiting |
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome |
- Blasts 5 Percent or More of Bone Marrow Nucleated Cells
- Childhood Acute Myeloid Leukemia
- Childhood Myelodysplastic Syndrome
- (and 6 more...)
|
- Drug: Asparaginase
- Drug: Asparaginase Erwinia chrysanthemi
- Drug: Cytarabine
- (and 5 more...)
|
Interventional
|
Phase 3 |
- Children's Oncology Group
- National Cancer Institute (NCI)
- Children's Oncology Group
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event-free survival (EFS)
|
256 |
All |
91 Days to 3 Years (Child) |
NCT02521493 |
AAML1531 NCI-2015-00324 s16-01673 U10CA180886 |
|
November 23, 2015 |
March 31, 2022 |
|
August 13, 2015 |
August 16, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - (and 170 more...)
|
|
78 |
NCT03269669 |
Recruiting |
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma |
- Grade 1 Follicular Lymphoma
- Grade 2 Follicular Lymphoma
- Grade 3a Follicular Lymphoma
- (and 2 more...)
|
- Drug: Bendamustine
- Drug: Cyclophosphamide
- Drug: Doxorubicin Hydrochloride
- (and 6 more...)
|
Interventional
|
Phase 2 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Complete response (CR)
- Sustained complete response rate (CR30) defined by centrally read positron emission tomography (PET)/computed tomography (CT)
- Progression-free survival (PFS)
- (and 6 more...)
|
150 |
All |
18 Years and older (Adult, Older Adult) |
NCT03269669 |
NCI-2017-00009 S1608 U10CA180888 |
|
August 10, 2017 |
December 31, 2022 |
December 31, 2022 |
September 1, 2017 |
February 22, 2019 |
|
- Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States - Alaska Women's Cancer Care
Anchorage, Alaska, United States - (and 344 more...)
|
|
79 |
NCT02883049 |
Recruiting |
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations |
- B Acute Lymphoblastic Leukemia
- Central Nervous System Leukemia
- Ph-Like Acute Lymphoblastic Leukemia
- (and 3 more...)
|
- Drug: Clofarabine
- Drug: Cyclophosphamide
- Drug: Cytarabine
- (and 15 more...)
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Comparison of disease-free survival (DFS) of children with high-risk (HR) B-acute lymphoblastic leukemia (ALL) (Completed effective March 19, 2018)
- DFS of children, adolescents, and young adults with very high-risk (VHR) B-ALL between arms (Completed effective February 15, 2017)
- Toxicity and tolerability of post-induction age-adjusted ITT compared to age-adjusted IT MTX in children with HR B-ALL (Completed effective March 19, 2018)
- (and 7 more...)
|
5956 |
All |
1 Year to 30 Years (Child, Adult) |
NCT02883049 |
NCI-2011-03797 CDR0000706370 COG-AALL1131 S12-01254 AALL1131 U10CA180886 U10CA098543 |
|
February 27, 2012 |
June 30, 2021 |
|
August 30, 2016 |
February 22, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - USA Health Strada Patient Care Center
Mobile, Alabama, United States - (and 236 more...)
|
|
80 |
NCT02339740 |
Recruiting |
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia |
- Acute Promyelocytic Leukemia With PML-RARA
|
- Drug: Arsenic Trioxide
- Drug: Cytarabine
- Drug: Dexamethasone
- (and 6 more...)
|
Interventional
|
Phase 3 |
- Children's Oncology Group
- National Cancer Institute (NCI)
- Children's Oncology Group
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event-free survival (EFS) in standard risk acute promyelocytic leukemia (APL) patients
- EFS in high risk APL patients
|
158 |
All |
12 Months to 21 Years (Child, Adult) |
NCT02339740 |
AAML1331 NCI-2014-02266 PAAML1331_A01PAMDREVW0 U10CA180886 |
|
June 29, 2015 |
June 30, 2021 |
|
January 15, 2015 |
February 22, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - USA Health Strada Patient Care Center
Mobile, Alabama, United States - Providence Alaska Medical Center
Anchorage, Alaska, United States - (and 171 more...)
|
|
81 |
NCT03150693 |
Recruiting |
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia |
- B Acute Lymphoblastic Leukemia
|
- Drug: Allopurinol
- Drug: Cytarabine
- Drug: Daunorubicin Hydrochloride
- (and 12 more...)
|
Interventional
|
Phase 3 |
- Alliance for Clinical Trials in Oncology
- National Cancer Institute (NCI)
- Alliance for Clinical Trials in Oncology
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
310 |
All |
18 Years to 39 Years (Adult) |
NCT03150693 |
A041501 NCI-2016-01981 U10CA180821 |
|
June 1, 2017 |
March 2023 |
August 2024 |
May 12, 2017 |
February 21, 2019 |
|
- Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States - Alaska Oncology and Hematology LLC
Anchorage, Alaska, United States - (and 198 more...)
|
|
82 |
NCT03057626 |
Recruiting |
Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma |
- Recurrent Neuroblastoma
- Stage 2A Neuroblastoma
- Stage 2B Neuroblastoma
- (and 3 more...)
|
- Other: Cytology Specimen Collection Procedure
- Other: Laboratory Biomarker Analysis
- Other: Quality-of-Life Assessment
|
Observational
|
|
- Children's Oncology Group
- National Cancer Institute (NCI)
- Children's Oncology Group
|
Other / NIH |
|
- Prevalence of specific late effects
- Prevalence of subsequent malignant neoplasm (SMN)
- Risk factors
- (and 2 more...)
|
400 |
All |
5 Years to 50 Years (Child, Adult) |
NCT03057626 |
ALTE15N2 NCI-2017-00170 COG-ALTE15N2 UG1CA189955 |
|
June 5, 2017 |
October 1, 2020 |
October 1, 2020 |
February 20, 2017 |
February 22, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 73 more...)
|
|
83 |
NCT01096368 |
Recruiting |
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma |
- Cellular Ependymoma
- Childhood Anaplastic Ependymoma
- Childhood Infratentorial Ependymoma
- (and 5 more...)
|
- Radiation: 3-Dimensional Conformal Radiation Therapy
- Drug: Carboplatin
- Drug: Cisplatin
- (and 5 more...)
|
Interventional
|
Phase 3 |
- Children's Oncology Group
- National Cancer Institute (NCI)
- Children's Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event-free survival (EFS)
- Overall survival (OS)
- Event free survival (EFS) of children with incompletely resected ependymoma who are unable to achieve a complete response (CR) by post-operative induction chemotherapy or by second surgery
- (and 6 more...)
|
500 |
All |
13 Months to 20 Years (Child, Adult) |
NCT01096368 |
ACNS0831 NCI-2011-02029 COG-ACNS0831 CDR0000668560 10-01676 U10CA180886 U10CA098543 |
|
March 29, 2010 |
December 31, 2021 |
|
March 31, 2010 |
February 22, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Cardon Children's Medical Center
Mesa, Arizona, United States - (and 206 more...)
|
|
84 |
NCT02567435 |
Recruiting |
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma |
- Alveolar Rhabdomyosarcoma
- Botryoid-Type Embryonal Rhabdomyosarcoma
- Embryonal Rhabdomyosarcoma
- (and 4 more...)
|
- Drug: Cyclophosphamide
- Biological: Dactinomycin
- Drug: Irinotecan Hydrochloride
- (and 6 more...)
|
Interventional
|
Phase 3 |
- National Cancer Institute (NCI)
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event-free survival (EFS)
- Overall survival (OS)
|
397 |
All |
up to 40 Years (Child, Adult) |
NCT02567435 |
NCI-2015-01644 ARST1431 U10CA180886 |
|
May 23, 2016 |
March 1, 2023 |
|
October 5, 2015 |
February 21, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - Anchorage Radiation Therapy Center
Anchorage, Alaska, United States - (and 334 more...)
|
|
85 |
NCT02900976 |
Recruiting |
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder |
- CD20 Positive
- EBV-Related Post-Transplant Lymphoproliferative Disorder
- Epstein-Barr Virus Positive
- (and 3 more...)
|
- Biological: Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes
- Other: Laboratory Biomarker Analysis
- Biological: Rituximab
|
Interventional
|
Phase 2 |
- Children's Oncology Group
- National Cancer Institute (NCI)
- Children's Oncology Group
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of patients assigned to Arm latent membrane protein-specific T-cells (LMP-TC) with successful LMP-specific T cell product match, were treated within two weeks of the expected start date, and received both weekly doses
- Percentage of patients successfully matched to a latent membrane protein (LMP)-specific T cell product derived from a third party LMP-specific T cell bank
- Progression-free survival (PFS)
- (and 6 more...)
|
90 |
All |
up to 29 Years (Child, Adult) |
NCT02900976 |
ANHL1522 NCI-2016-01110 U10CA180886 |
|
March 6, 2017 |
December 31, 2021 |
December 31, 2021 |
September 15, 2016 |
February 22, 2019 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - Loma Linda University Medical Center
Loma Linda, California, United States - (and 31 more...)
|
|
86 |
NCT03397394 |
Recruiting |
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma |
- Bladder Cancer
- Urothelial Carcinoma
- Metastatic Urothelial Carcinoma
- (and 5 more...)
|
|
Interventional
|
Phase 2 |
- Clovis Oncology, Inc.
- Foundation Medicine
- Clovis Oncology, Inc.
|
Industry |
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate (ORR)
- Duration of response (DOR)
- Progression-free survival (PFS)
- (and 5 more...)
|
200 |
All |
18 Years and older (Adult, Older Adult) |
NCT03397394 |
CO-338-085 |
ATLAS |
June 1, 2018 |
December 2019 |
June 2020 |
January 12, 2018 |
February 7, 2019 |
|
- Pinnacle Oncology, Honor Health
Scottsdale, Arizona, United States - University of California San Diego (UCSD), Moores Cancer Center
La Jolla, California, United States - University of California, Los Angeles (UCLA)
Los Angeles, California, United States - (and 53 more...)
|
|
87 |
NCT02348216 |
Recruiting |
Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma |
- Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Relapsed Diffuse Large B-Cell Lymphoma
- Transformed Follicular Lymphoma (TFL)
- (and 2 more...)
|
- Biological: Axicabtagene Ciloleucel
- Drug: Fludarabine
- Drug: Cyclophosphamide
|
Interventional
|
Phase 1 Phase 2 |
- Kite, A Gilead Company
- Gilead Sciences
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase 1 Study: Percentage of Participants Experiencing Adverse Events defined as Dose Limiting Toxicities (DLTs)
- Phase 2 Pivotal Study: Overall Response Rate (ORR)
- Phase 2 Safety Management Study: Incidence and Severity of CRS and Neurologic Toxicities
- (and 13 more...)
|
250 |
All |
18 Years and older (Adult, Older Adult) |
NCT02348216 |
KTE-C19-101 |
ZUMA-1 |
January 2015 |
May 2020 |
October 2034 |
January 28, 2015 |
February 22, 2019 |
|
- Banner MD Anderson
Gilbert, Arizona, United States - City of Hope
Duarte, California, United States - UC San Diego Moores Cancer Center
La Jolla, California, United States - (and 33 more...)
|
|